-
Epipens vs nasal epinephrine?
EpiPen(R), the leading auto-injector product, is on track to become a billion dollar product in 2014 according to its distributor Mylan Inc. In 2013, G2B Pharma and SNBL (Japan) conducted a successful proof of concept study which showed that nasally administered G2B011 demonstrates rapid and high absorption comparable to EpiPen(R), and has the potential to…
-
Charity needs to think big
Charity is stuck in small scale, limited vision with no potential to deal with the massive social problems they often seek to address. They are unable to attract the best talent by offering competitive wages, unable to advertise, unable to invest in growth (cf Amazon, no profits for 6yrs), unable to take risks due to…